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ABSTRACT
Pancreatic Ductal Adenocarcinoma (PDAC) is a highly aggressive malignancy 
characterized by rapid progression, invasiveness and resistance to treatment. We 
have previously demonstrated that most PDAC patients have circulating antibodies 
against the glycolytic enzyme alpha-enolase (ENO1), which correlates with a better 
response to therapy and survival. ENO1 is a metabolic enzyme, also expressed on 
the cell surface where it acts as a plasminogen receptor. ENO1 play a crucial role in 
cell invasion and metastasis by promoting plasminogen activation into plasmin, a 
serine-protease involved in extracellular matrix degradation. The aim of this study 
was to investigate the role of ENO1 in PDAC cell invasion. We observed that ENO1 
was expressed on the cell surface of most PDAC cell lines. Mouse anti-human ENO1 
monoclonal antibodies inhibited plasminogen-dependent invasion of human PDAC 
cells, and their metastatic spreading in immunosuppressed mice was inhibited. 
Notably, a single administration of Adeno-Associated Virus (AAV)-expressing 
cDNA coding for 72/1 anti-ENO1 mAb reduced the number of lung metastases in 
immunosuppressed mice injected with PDAC cells. Overall, these data indicate that 
ENO1 is involved in PDAC cell invasion, and that administration of an anti-ENO1 mAb 
can be exploited as a novel therapeutic option to increase the survival of metastatic 
PDAC patients.
INTRODUCTION
Pancreatic Ductal Adenocarcinoma (PDAC) is the 
fourth leading cause of cancer mortality in developed 
countries. Despite the available treatment, PDAC has the 
worst prognosis of all major malignancies, with a 5-year 
survival rate of 6% and a median survival of 6 months 
after diagnosis [1, 2]. The high mortality rate associated 
with PDAC is almost equal to the incidence rate, and is 
caused by the high frequency of metastatic disease found 
at diagnosis [3, 4].
The plasminogen system is involved in tumor 
growth, invasion and metastasis [5-7]. Urokinase (uPA) 
and tissue (tPA) plasminogen activators released from 
cancer cells catalyze the proteolytic conversion of 
plasminogen to plasmin, leading to degradation of the 
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extracellular matrix (ECM), thus facilitating cancer 
cell invasion [5-8]. The uPA receptor (uPAR) is a cell 
membrane-anchored protein which aids the accumulation 
of plasminogen at the cell surface [5]. Binding proteins 
for plasminogen include alpha-Enolase (ENO1), Annexin 
2 (ANX2) and Cytokeratin 8 (CK8) [9]. Among these, 
ENO1 has been classified as a pancreatic cancer-associated 
antigen as it is overexpressed in PDAC and induces both 
humoral and T cell-specific responses in patients [10, 11].
In this study, a multiple approach was adopted to 
investigate the role of ENO1 in the invasion and metastasis 
of PDAC, and to develop possible therapeutic options, 
based on ENO1 regulation, aimed to counteracting the 
invasiveness of this tumor. We evaluated i) the expression 
of ENO1, uPA and uPAR and of plasminogen-induced 
migration, in a panel of eight PDAC cell lines; ii) the 
in vitro and in vivo effects of anti-ENO1 monoclonal 
antibodies (mAbs); iii) the in vitro and in vivo effects of 
ENO1 silencing or mutations of its plasminogen-binding 
site, and iv) the effect of administering recombinant 
adeno-associated viral vector (AAVV) for the expression 
of complete anti-ENO1 mAb in in vivo metastatization.
RESULTS
Analysis of ENO1, uPAR and uPA expression in 
PDAC cell lines
Flow-cytometry, using specific 72/1 mAb, revealed 
that ENO1 was expressed on the surface of the majority 
of the tumor cell lines tested, namely PT45, MIA PaCa-
2, Hs766T, T3M4, CFPAC-1, and L3.6pl. High ENO1 
expression was found in T3M4, CFPAC-1 and L3.6pl, 
cells; there was intermediate ENO1 expression in MIA 
PaCa-2, Hs766T, and PT45 cells, and low or no ENO1 
expression in BxPC-3 and PANC-1 cells (Fig. 1a upper 
panel). By contrast, all cell lines expressed similar levels 
of total ENO1 (Fig. 1a lower panel).
In addition to plasminogen receptors, such as 
ENO1, plasminogen activation requires the plasminogen 
activation system, as such, uPA and uPAR expression in 
PDAC cell lines was evaluated. After flow-cytometry 
analysis, we observed high levels of uPAR in PT45 and 
CFPAC-1 cells, intermediate levels in BxPC-3, PANC-1, 
MIA PaCa-2, and Hs766T cells, and low or zero levels in 
T3M4 and L3.6pl cells (Fig. 1b). uPA expression was high 
in BxPC-3, PANC-1 and CFPAC-1 cells, intermediate in 
PT45, and T3M4 cells, and low or absent in MIA PaCa-2, 
Hs766T and L3.6pl cells (Fig. 1c).
Effect of the blockade of ENO1 on plasminogen-
dependent invasion of PDAC cells
In the presence of plasminogen, CFPAC-1 cells 
were strongly invasive compared to those in the absence 
of plasminogen (Supplementary data Fig. S1a and b). 
No increase in invasion was observed in the presence 
of plasminogen for any of the other cell lines (Fig. S1a, 
b). As the CFPAC-1 cells produced uPA and expressed 
both surface uPAR and ENO1, they were able to invade 
in response to plasminogen. Nevertheless, as TGF-β has 
been shown to up-regulate both uPA and uPAR [12], its 
effect on plasminogen-dependent invasion was evaluated. 
In ENO-1 expressing T3M4 and in L3.6pl cells, TGF-β 
increased the expression of uPAR and uPA (Fig. S1c) 
and rendered them responsive to plasminogen-dependent 
invasion (Fig. S1d and Table S1). 
In the presence of anti-ENO1 mAb, the 
plasminogen-dependent invasiveness of both CFPAC-1 
(Fig. 2a) and TGF-β-treated-T3M4 (Fig. 2b) cells was 
significantly reduced. The extent of this reduction 
was similar to that induced in CFPAC-1 cells by the 
plasminogen system inhibitor EACA (Fig. 2a). By 
contrast, BxPC-3 cells, which expressed very low levels 
of ENO1, did not invade in the presence of plasminogen, 
and were not affected by the addition of anti-ENO1 mAb 
(Fig. 2a lower panel). These results were also confirmed 
using the Oris TM -FLEX Platypus Kit, in which cells 
were completely plunged into Matrigel and their invasion 
was evaluated in the absence of chemotactic stimuli, by 
measuring their ability to fill a central hole in the well 
(Fig. 2c). 
In the presence of plasminogen, a similar growth 
pattern was observed when PDAC cells were cultured 
with anti-ENO1 mAb or isotype-control Ab (Fig. S2). This 
ruled out the possibility that the inhibitory effect of the 
anti-ENO1 mAb on migration is due to interference with 
the growth of tumor cells.
Effect of mutation of ENO1 plasminogen binding 
sites on the plasminogen-dependent invasion of 
PDAC cells
ENO1 expression was silenced in CFPAC-1 cells 
with a lentivirus delivering an shRNA targeting ENO1 
or the 3’UTR (shENO1). A scrambled shRNA (shCTRL) 
was used as a control. Both ENO1 mRNA (Fig. S3a 
upper panel) and protein levels (Fig. S3a lower panel), 
as well as plasminogen-induced invasion (Fig. S3b) were 
efficiently reduced after silencing in CFPAC-1 shENO1 
cells. Infection of CFPAC-1 cells with a second shRNA 
targeting the ENO1 CDS region (shENO1#2) gave similar 
results (Fig. S3). All subsequent experiments were carried 
out using CFPAC-1 shENO1 cells. 
FACS analysis revealed that uPA and uPAR 
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Fig.1: Analysis of ENO1, uPAR and uPA expression in PDAC cell lines. PDAC cell lines were incubated with anti-ENO1 72/1 
mAb (solid histogram a), anti-uPAR antibody (solid histogram b), anti-uPA (solid histogram c) or an isotype-matched control antibody 
(open histogram) and analyzed by flow-cytometry. To evaluate intracellular expression of ENO1 (a, lower panel), Western blot analysis was 
performed on whole cell lysates of all PDAC cell lines with anti-ENO1 72/1 mAb. Results were normalized using β-Actin.  A representative 
of three independent experiments is shown.
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expression was not modified by ENO1 silencing in 
CFPAC-1 cells (Fig. S3c). 
To assess the contribution of ENO1 to PDAC 
invasion, shENO1 cells were transfected with a mutated 
form of ENO1 (shENO1+TM), in which three lysines 
of the plasminogen binding site at the C-terminal [13] 
were substituted with three arginines, resulting in a non-
functional plasminogen binding site (Fig. 3a). shENO1 
cells transfected with a wild type full-length exogenous 
ENO1 (shENO1+WT) or Empty vector (shENO1+Empty) 
were used as a controls. WB analysis showed that 
shENO1+WT or shENO1+TM rescued ENO1 protein 
levels (Fig. 3b upper panel). Flow cytometric analysis 
showed a lack of ENO1 surface expression in shENO1 
and shENO1+Empty (Fig.3b lower panel and not shown) 
whereas ENO1 surface expression in shENO1+WT 
or shENO1+TM was rescued (Fig. 3b lower panel). 
These data demonstrated that the triple mutation in the 
plasminogen binding site resulted in the inability of ENO1 
to bind plasminogen without its cell surface expression 
being affected.
Cells were then tested for invasive capacity in 
response to plasminogen. Control shENO1 CFPAC-1 
cells failed to invade through the Matrigel, whereas 
shENO1+WT cells recovered this ability, but to a lesser 
extent compared to CFPAC-1 shCTRL cells (Fig. 3c). 
Notably, shENO1+TM cells significantly reduced invasion 
in response to plasminogen compared to the shENO1+WT 
cells (Fig. 3c). To confirm the contribution of ENO1 to in 
vivo invasion and metastasis, NSG immunocompromised 
mice were injected i.v. with shENO1+TM, shENO1+WT 
or shENO1+Empty CFPAC-1 cells. On day 28, post-
mortem observations confirmed a significantly reduced 
metastatic area in the lungs of mice injected with 
shENO1+Empty or with shENO1+TM cells versus mice 
injected with shENO1+WT CFPAC-1 cells (Fig. 3d). 
Fig.2: Anti-ENO1 72/1 mAb inhibits plasminogen-dependent invasion of PDAC cells. (a) CFPAC-1 (upper panel), BxPC3 
(lower panel) and T3M4 (b) were placed on Matrigel-coated transwell filters and plasminogen (1 μg/ml or 10 μg/ml), anti-ENO1 mAb 72/1 
(50 μg/ml) or an isotype-matched IgG1 mAb (50 μg/ml), EACA (50mM) and TGF-β (10 ng/ml) were added in appropriate conditions. Data 
are reported as mean ± SEM of Optical Density units (OD) and the different conditions were repeated in triplicate. (c) Effect of anti-ENO1 
72/1 mAb on migration in Matrigel (OrisTM Platipus kit) of CFPAC-1 (upper panel) and BxPC3 (lower panel) cultured in the presence of 50 
μg/ml of anti-ENO1 or IgG1 control mAb with or without plasminogen (40 µg/ml). Images are taken at x5 magnification. A representative 
of three independent experiments is shown. *p<0.05; **p<0.01;***p<0.001
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Anti-ENO1 mAb blocks liver metastasis in an 
orthotopic pancreatic tumor model
To better characterize the role of ENO1 in in vivo 
tumor spreading, PANC-1/P cells with low expression of 
surface ENO1 were orthotopically injected into pancreases 
of NOD-SCID mice. Metastatic cells were harvested from 
livers and cultured, and were designated as PANC-1/M. 
Western blot analysis of total ENO1 protein showed that 
its expression level in PANC-1/P cells was significantly 
up-regulated, compared to that in normal-like human 
pancreatic duct epithelial cells, HPDE (Fig. 4a left). 
Conversely, although the total amount of ENO1 was 
not increased in metastatic PANC-1/M cells, its surface 
distribution was clearly augmented in these cells (Fig. 4a 
right), confirming that surface ENO1 may play a crucial 
role in tumor metastasis.
To confirm the potential therapeutic use of an 
anti-ENO1 Ab for metastatic PDAC, experiments were 
conducted with a different anti-ENO1 mAb, namely 
E10A. The invasion of metastatic PANC-1/M cells treated 
with the anti-ENO1 mAb was significantly suppressed 
in a dose-dependent manner (Fig. 4b). In addition, these 
cells were orthotopically injected into the pancreases of 
NOD-SCID mice, followed by i.v. administration of the 
anti-ENO1 mAb or its isotype mAb at 2h and 24h post-
inoculation. Metastatic tumor cells were fluorescently 
tracked by the IVIS system, showing that, in the orthotopic 
model, the liver was the major target for tumor metastasis 
of PANC-1/M cells, although a few metastatic colonies 
were detected in lungs and spleens (Fig. 4c upper left). 
Although two control mice died at 2 weeks prior to the 
completion of the experiments, the number and tumor 
Fig.3: Plasminogen-dependent invasion of CFPAC-1 shENO1 transfected with WT, TM or Empty vector. (a) Upper 
panel, a schematic representation of plasminogen-binding sites on ENO1 bearing mutations on lysines 420, 422 and 434 is shown. Lower 
panel, plasminogen binding to recombinant ENO1 WT or rENO1 TM was evaluated by ELISA. Data are reported as mean ± SEM of 
Optical Density units (OD) and the different conditions were repeated in triplicate. (b) CFPAC-1 shCTRL, CFPAC-1 shENO1+Empty, 
shENO1+WT, shENO1+TM cell lines were checked for the expression of ENO1 in the total cell lysates (b, upper panel). Results were 
normalized using β-Actin. For determining surface expression, cells were incubated with anti-ENO1 72/1 mAb (solid histogram) or an 
isotype-matched control antibody (open histogram) and analyzed by flow-cytometry (b, lower panel). (c) Invasion of CFPAC-1 shCTRL, 
shENO1+WT, shENO1+TM or shENO1+Empty cells in the presence or absence of 10 μg/ml plasminogen. Results represent the percentage 
of plasminogen-dependent invasion calculated as: (OD of migrated cells in the presence of plasminogen / OD of migrated cells in the 
absence of plasminogen) x100. (d) Growth of CFPAC-1 shENO1+WT, shENO1+TM and shENO1+Empty cells in the lungs of i.v. injected 
NSG mice. Bars represent the percentage of tumor area calculated as: (tumor area / total area) x100. Data are reported as mean ± SEM of 
five mice per group. *p<0.05; **p<0.01;***p<0.001 Statistic analysis respect to CFPAC-1 shENO1+Empty (*), to CFPAC-1 shENO1+WT 
($) or to CFPAC-1 shCTRL (§).
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volume of visible metastatic colonies in livers of mice 
treated with the anti-ENO1mAb were markedly decreased 
compared to mice treated with the control mAb (Fig. 4c 
upper right). This observation was further confirmed by 
directly weighing each organ. Again, treatment with the 
anti-ENO1 mAb substantially reduced metastatic tumor 
masses in livers (Fig. 4c lower panel). The average 
weights of the livers of the anti-ENO1 mAb-treated mice 
were comparable to those of age-matched un-injected 
mice. 
Anti-ENO1 mAb reduces the in vivo growth and 
metastasis of CFPAC-1 cells
To prove the therapeutic effect of anti-ENO1 mAb, 
SCID-beige mice were injected i.v. with luciferase-
expressing CFPAC-1 cells, and treated biweekly until 
sacrifice with anti-ENO1 mAb or isotype-matched control 
mAb. Notably, CFPAC-1 cells resulted in large masses at 
the lymph node level, prior to lung tumors. Anti-ENO1 
mAb treatment led to a reduced number of tumor masses 
compared to control treatment. This effect was most 
evident from day 14 onwards, and the difference between 
anti-ENO1 mAb-treated mice and control mice was even 
greater on day 28 (Fig. 5a left). Post-mortem observations 
confirmed a reduced number of tumor masses in anti-
ENO1 mAb-treated mice compared to control mice (Fig. 
5a right). Only a few mice developed lung metastasis (4 
out of 15 mice), confirmed by hematoxylin-eosin stained 
lung sections (data not shown). This number of mice 
was too small to appreciate significant differences in the 
number and size of lung metastasis between treated and 
control groups.
An additional experiment was performed using NSG 
mice. Mice were pre-treated for 3 days with anti-ENO1 or 
control Abs prior to tumor challenge. At day 0, NSG mice 
were injected i.v. with luciferase-expressing CFPAC-1 
cells, and treated biweekly with the mAbs until sacrifice. 
As early as day 14 after tumor injection, anti-ENO1 mAb-
treated mice emitted a significantly reduced number of 
photons compared to the control group, as evaluated by 
IVIS spectrum technology (Fig. 5b). 
An AAVV strongly increases the anti-tumor role 
of anti-ENO1 mAb
To further enhance the effect of anti-ENO1 mAb by 
continuous production of the antibody, NSG mice were 
injected with 1x1011 genocopies of Adeno-Associated 
Viral (AAV) vector expressing anti-ENO1 72/1 mAb, 
or control AAV, into femoral muscle, 7 days prior to i.v. 
CFPAC-1 cell injection (Fig. 5c upper panel). At day -7, 7 
and 28, blood from mice was taken and analyzed for the 
presence of anti-ENO1 mAb. A progressively increasing 
concentration of anti-ENO1 mAb was observed, showing 
that AAVV facilitated a continuous, long-lasting and 
sustained production of circulating anti-ENO1 mAb (Fig. 
5c lower panel). On day 28, mice injected with AAVV 
expressing anti-ENO1 mAb showed a significant decrease 
in lung metastases compared to control mice (Fig. 5d).
DISCUSSION
Evidence from experimental models suggests 
that cell-associated plasminogen and its activators play 
a central role in tumor invasion [5, 14-16]. Numerous 
extracellular proteins have been identified as plasminogen 
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Fig.4: Capacity of the anti-ENO1 E10A mAb to inhibit in vitro and in vivo invasion of pancreatic cancer cells. (a) Left 
panel, Western blot analysis of total ENO1 expression in HPDE, PANC-1/P and PANC-1/M cells using an in-house purified rabbit antiserum 
against ENO1. β-Actin was used as a loading control. Right panel, flow-cytometric analysis of cell-surface ENO1 in HPDE, PANC-1/P and 
PANC-1/M cells using anti ENO1 E10A (empty area) or its isotype-control Ab (black area). (b) Dose-dependent inhibition of cell invasion 
by the anti ENO1 E10A mAb in PANC-1/M cells. Cells that degraded tumor-associated matrix and migrated through the membrane were 
stained and quantified with the ImageJ image-processing software. One representative pair is shown in the upper panel. Data are expressed 
as means ± SEM and are represented as a fold-decrease in the invasive ability of cells treated with different doses of the anti ENO1 E10A 
mAb, compared with that of cells treated with the control antibody (lower panel). (c) Blockade of liver metastasis by the anti-ENO1 E10A 
mAb in an orthotopic pancreatic tumor model. Intravenous administration of the anti-ENO1 E10A (250 μg/mouse) or control mAbs was 
performed at 2 h and 24 h after tumor inoculation. The tissue distribution of the luciferase-expressing cells was monitored using the IVIS 
image system every 2 weeks for a total of 6 weeks. Mice were sacrificed after 6 weeks. Organs from one pair of representative mice treated 
with the anti-ENO1 or control mAbs, as indicated, were photographed (upper left). Metastatic tumors in different organs were visualized 
by exposure for 10s and 1s, respectively, in the luminescent mode of the IVIS system. Upper right; after mice were sacrificed, the number 
and volume of metastatic tumor nodules in livers of mice treated with the anti- ENO1 (black) or control (gray) mAbs were quantified. 
Data are expressed as the mean ± SEM of each group of mice. Lower panel, intact individual organs obtained from mice treated with the 
anti-ENO1 (black) or control (gray) mAbs were weighed, as indicated at the bottom. Quantitative data from each treatment are presented 
in the histograms. Normal livers taken from age-matched, untreated mice (white) served as healthy controls; * and ** indicate P<0.05 and 
P<0.01, respectively. For the in vivo experiment, five mice per group were used.
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receptors, including ENO1, ANX2 and CK8 [9], which are 
often de-regulated in cancer. 
In this study, we identified ENO1 on the surface of 
human PDAC cells. Notably, among the eight cell lines 
tested, ENO1 was expressed at intermediate or high 
levels in metastatic cell lines (Hs766T[17], T3M4[18], 
CFPAC-1[19], L3.6pl[20]), and was absent or expressed 
at lower levels in primary tumor-derived cell lines 
(BxPC3[21], PANC-1[22], PT45[23], Mia-PaCa2[24]). 
Ex vivo analysis of PANC-1 cells from a liver metastasis 
showed that the surface expression of ENO1 was higher 
compared to the parental cells from the primary tumor. 
This suggests that spreading and invasion of PDAC cells 
is strictly related to the high cell surface expression of 
ENO1, which, in turn, facilitates binding of elevated 
concentrations of plasminogen at the cell surface. 
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Fig.5: Effect of multiple injection or single injection of AAVV-anti-ENO1 72/1 mAb in the pancreatic mouse model. 
Effect of biweekly i.p. injections of anti-ENO1 72/1mAb or an IgG1 isotype-matched control mAb (500 µg per mouse) in SCID-beige (a) or 
NSG (b) mice injected i.v. with luciferase-expressing CFPAC-1 cells were monitored by in vivo imaging. Image shows three representative 
mice for each treatment group followed during the experiment (day 0, day 14 and day 28). Graph shows the mean ± SEM number of tumor 
masses from each out of five mice. (b) From day 0 to day 14, tumor growth was monitored with IVIS spectrum technology. Results are 
expressed as absolute number of emitted photons at day 14. (c) Upper panel, schematic representation of the recombinant AAV vector 
expressing the anti-enolase 72/1.11 IgG1. TR: AAV terminal repeats sequences; CMV: cytomegalovirus promoter; S: secretion signal; VL: 
mAb 72/1.11 VL region; Cκ: mouse κ constant region; F: furin cleavage site; 2A: FMDV peptide 2A sequence; VH: mAb 72/1.11 VH region; 
Cγ1: mouse γ1 constant region. Lower panel, evaluation of anti-ENO1 mAb concentration in sera from NSG mice intramuscularly injected 
with AAVV-anti-ENO1 72/1 mAb and after 7 days i.v. with CFPAC-1 by ELISA. (d) On day 28 after tumor challenge, mice were sacrificed 
and lung metastases were stained with hematoxylin-eosin and counted. Bars represent the percentage of tumor area calculated as follows: 
(tumor area / total area) x 100. Representative images of lung sections from control and treated mice are shown. For the in vivo experiment, 
five mice per group were used. *p<0.05; **p<0.01;***p<0.001
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Plasminogen expressed at the cell surface activates 
plasmin, increasing the ability of PDAC cells to degrade 
the ECM. However, the mechanism by which ENO1 is 
expressed at the cell surface is still unknown. Hypoxia, 
a condition that characterizes tumor growth in vivo, up-
regulates ENO1 expression [25-27]; therefore, we cannot 
rule out that the surface expression of ENO1 results from 
a general increase of ENO1 transcription and translation. 
However, as ENO1 is phosphorylated, methylated and 
acetylated [26, 28] in PDAC cells, the role of these post-
translational modifications in the regulation of surface 
localization of ENO1 in PDAC cells should also be 
considered.
In this study, we demonstrated that the in vitro and 
in vivo blockade of ENO1 by treatment with two different 
specific mAbs reduced the migration and invasion capacity 
of PDAC cells. Indeed, the transduction of wild type 
ENO1, but not ENO1 carrying the mutated plasminogen-
binding site, restored the plasminogen-dependent invasion 
of CFPAC-1 cells that had been previously suppressed due 
to ENO1 silencing. Taken together, these data strongly 
support the notion that ENO1 is involved in plasminogen-
dependent invasion of PDAC. 
In vitro, CFPAC-1 cells displayed an invasive 
ability in the presence of plasminogen, which could be 
ascribed to the endogenous expression of uPA and uPAR, 
as well as ENO1. Moreover, after exposure to TGF-β 
ENO1-expressing T3M4 and L3.6pl cells were induced 
to up-regulate uPA and uPAR and to invade in response 
to plasminogen (Table S1). As the invasion of all these 
cell lines was inhibited by anti-ENO1 mAb this implies 
that ENO1 regulated the PDAC metastatic process in 
vivo where the TGF-β is provided [12, 29-33]. Metastatic 
PANC-1/M cells derived from a liver metastasis, following 
orthotopical injection of PANC-1 cells in the pancreas, 
expressed higher levels of surface ENO1 compared to the 
primary tumor cells, suggesting a role for surface ENO1 
in facilitating tumor spreading.
In vivo, blockade of ENO1 by two specific anti-
ENO1 mAbs reduced tumor spreading in different mouse 
xenograft tumor models. In the SCID-beige tumor model, 
we observed a particular pattern of tumor dissemination, 
as cells grew in lymph-nodes without forming organ 
metastasis. Since PDAC cells express CXCR4, they can 
migrate towards the gradient of CXCL12 released by 
lymphoid organs and localize in lymph nodes [34]. By 
contrast, NGS null mice injected with CFPAC-1 cells did 
not develop lymph-node masses, probably because they 
lack functional lymph-nodes, but displayed classical lung 
tumor spreading. In both cases, specific treatment with 
anti-ENO1 mAb was effective in inhibiting tumor growth. 
Finally, in NOD-SCID mice that were orthotopically 
injected with PANC-1/M cells, the anti-ENO1 mAb was 
effective in inhibiting the spreading of liver metastasis.
The innovative use of AAV technology to increase 
the efficacy of anti-ENO1 mAb treatment in mice 
is noteworthy, and results in dramatic inhibition of 
metastasis in the NSG model. AAVV is non-pathogenic 
and the recombinant vector retains none of the viral genes, 
making it a safer alternative to live bacterial strains. 
The lack of the Rep gene of the AAV vector also limits 
its integration potential, and the vast majority of AAV 
vectors are thought to remain episomal [35]. This strategy 
has many advantages, namely resistance to the effects of 
pH; a localized or broad cellular tropism depending on 
the AAVV serotype; efficient gene transfer; persistence 
of gene expression, and low toxicity in vivo. Moreover, 
AAV-based therapeutic strategies have been tested in 
humans, and several clinical trials have been shown to be 
successful in terms of initial safety and proof of concept 
[36].
Increased expression of ENO1 has been observed 
in many tumors [9, 26, 37, 38], together with its ability 
to induce an immune response both in vitro and in vivo 
[10, 39-42]. Recently, we have demonstrated that ENO1 is 
expressed on the surface of lung tumor cells and promotes 
ECM degradation and invasion through a plasminogen-
dependent process [16]. Our findings strongly suggest that 
surface ENO1 is involved in the invasion of PDAC cells, 
and that blockade of the ENO1/plasminogen interaction, 
by using an AAVV-ENO1 mAb, could provide a new 
therapeutic approach for the treatment of metastatic PDAC 
patients.
MATERIALS AND METHODS
Cell Culture
Human PDAC cell lines used: CFPAC-1, MIA PaCa-
2, BxPC-3 (all from ECACC), T3M4, PANC-1, Hs766T, 
L3.6pl and PT45 (all kindly provided by Prof. Paola 
Nisticò, Regina Elena National Cancer Institute, Rome, 
Italy). Cell lines were cultured in DMEM (Lonza, Milan, 
Italy) supplemented with 10% FBS (Lonza), L-Glutamine 
(GE Healthcare, Milan, Italy) and 50µg/ml of gentamicin 
(Gentalyn 40mg/ml, Essex Italia, Segrate, MI, Italy) 
at 37°C in a 5% CO2 atmosphere. Cells were detached 
using a solution of PBS containing 0.25% Trypsin-
EDTA. HPDE cells were cultured in Keratinocyte-SFM 
medium (Invitrogen, Carlsbad, CA) supplemented with 
pituitary extract and recombinant EGF. PANC-1/P cells 
were generated by transduction of PANC-1 cells with dual 
reporter lentiviral particles (GeneCopoeia, Rockville, MD) 
to co-express GFP and firefly luciferase (Luc), followed 
by selection of stable transfectants using BD FACSJazz 
(BD Biosciences, San Jose, CA). PANC-1/M cells were 
obtained from metastatic liver tumors developed in an 
orthotopic pancreatic mouse model using PANC-1/P cells.
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Flow cytometric analysis
Cells (1x105) were incubated with a primary mAb 
or an isotype-matched negative control antibody for 20 
min at 4°C. The following primary Abs were used: mouse 
anti-human ENO1 72/1 IgG1 mAb (10µg/ml) [43] and 
rabbit anti-human uPAR polyclonal antibody (10µg/ml; 
Santa Cruz Biotechnology by D.B.A. Italia, Segrate, MI, 
Italy). An irrelevant murine IgG1 was used as a negative 
control (Dako, Milan, Italy). Cells were then incubated, 
accordingly, with a secondary biotinylated rabbit 
polyclonal anti-mouse F(ab’)2 Ig antibody (20 min at 4°C) 
followed by phycoerythrin (PE)-conjugated streptavidin 
(SAPE), or Alexa Fluor 488 Goat anti-Rabbit IgG (H+L) 
antibody (LifeTechnologies, Monza, MB, Italy), for 20 
min at 4°C. For detection of uPA, cells were fixed with 4% 
paraformaldehyde (20 min at room temperature (RT) and 
then permeabilized with 5% saponin. Cells were incubated 
with a mouse anti-human uPA mAb (0.5 µg/ml; abcam 
by Prodotti Gianni, Milan, Italy). An irrelevant murine 
IgG1 was used as a negative control (Dako). Cells were 
then incubated with a secondary PE goat anti-mouse IgG 
antibody (BioLegend by Campoverde, Milan, Italy) for 
20 min at 4°C. Following this, cells were re-suspended in 
Dulbecco’s Phosphate-Buffered Saline (DPBS), acquired 
with a FACSCalibur and analyzed using the CellQuest 
program (BD Bioscience, Buccinasco, MI, Italy). PANC-
1/P, PANC-1/M and HPDE cells were stained with the 
mouse anti-human ENO1 E10A IgG2a mAb or its isotype 
control (1.5 μg/mL) for 30 min on ice, visualized with goat 
anti-mouse F(ab’)2 conjugated PE (2.5 μg/mL; Jackson 
ImmunoResearch, Cambridgeshire, UK), and analyzed 
using the FACScan flow cytometer (BD Biosciences).
Western blot analysis
PDAC cells (1x107) from the various cell lines were 
harvested, lysed, resolved and transferred to nitrocellulose 
membranes, as previously described [40]. Membranes 
were incubated for 1 h at RT with anti-ENO1 72/1 mAb or 
rabbit polyclonal anti- β-Actin antibody (Sigma-Aldrich), 
at dilutions of 1:2000 in Tween-Tris-Buffered Saline 
(TTBS) and then probed with a horseradish peroxide 
(HRP)-conjugated anti-mouse IgG (Santa Cruz) or 
HRP-conjugated goat anti-rabbit Ig secondary antibody 
(Sigma-Aldrich) at dilutions of 1:2000. For Western blot 
analysis of ENO1 in PANC-1/P, PANC-1/M and HPDE 
cells, membranes were probed with in-house purified 
rabbit antiserum against ENO1 or with mouse antibody 
specific to β-Actin (Sigma St. Louis, MO, USA) as a 
protein loading control. Immunocomplexes were detected 
by probing with appropriate secondary antibodies 
conjugated with HRP (Jackson ImmunoResearch), and 
were visualized using the SuperSignal detection system 
(Thermo Fisher, Waltham, MA, USA).
In vitro chemo-invasion assay
Porous (8 μm pore size) tissue culture inserts (6.5 
mm diameter) (Costar by Sigma-Aldrich) were coated with 
50μl of Matrigel (BD Biosciences) diluted at 1:8 in serum-
free DMEM, and incubated for 4 h at 37°C. Inserts were 
placed in a 24-well plate containing 0.6 ml/well of DMEM 
supplemented with 3% FBS. Cells (1x105/well) were 
seeded in triplicate in serum-free medium in the upper 
chamber and incubated for 48h at 37°C. Plasminogen 
Glu-Type (1µg/ml or 10µg/ml; Calbiochem by D.B.A.), 
anti-ENO1 72/1 mAb or IgG1 isotype-matched control 
antibody (50µg/ml; anti-intracellular domain of the IFN-
γR2, γR37) [44], Epsilon-Amino-Caproic Acid (EACA) 
(50mM; Calbiochem) and TGF-β (1ng/ml or 10ng/ml; 
Peprotech by Tebu-bio, Magenta, MI, Italy) were added to 
appropriate inserts. After incubation, invasive cells were 
fixed in 2% glutaraldehyde, stained with Crystal Violet 
(Sigma-Aldrich), treated with a 10% acetic acid solution 
(Sigma-Aldrich), and eluates were read at 570nm with a 
spectrophotometer (Bio-Rad laboratories, Segrate, MI, 
Italy). For analysis of the HPDE, PANC-1/P and PANC-
1/M cell lines, 5x104 cells/well were seeded and incubated, 
as described above, with anti-ENO1 E10A or with control 
mAb. After incubation for 24 h, cells were fixed, stained 
with Gimsa, and quantified by the ImageJ analysis [45]. 
Invasion assays in the presence of plasminogen alone 
(40µg/ml) or with anti-ENO1 72/1 mAb (50µg/ml) or with 
mouse IgG1 control (50µg/ml) were also carried out with 
a Cell Migration Assembly Kit, OrisTM - FLEX (Platipus 
Technology by TEMA Ricerca, Bologna, Italy) according 
to the manufacturer’s instructions.
Silencing of ENO1 in the PDAC cell line CFPAC-1
Two Mission short hairpin RNA (shRNA), one 
targeting the 3’UTR of the gene coding for ENO1 
(TRCN0000029324) and one targeting the CDS 
region (TRCN0000029327) were used to transform 
bacteria (Sigma-Aldrich, Milan, Italy); plasmids were 
purified with the PureLink HiPure Plasmid Maxiprep 
Kit (LifeTechnologies). Lentiviruses were produced 
by co-transfecting 293T packaging cells (Clontech by 
Diatech Lab Line Srl, Jesi, AN, Italy) with pLKO.1 puro 
vector containing the shRNA and the helper vectors 
pCMVΔ8.74 (Add gene, Cambridge, MA, USA) and 
pVSV-G (Clontech), using the calcium phosphate method. 
Lentiviruses collected at 24h after transfection were used 
for the transduction of the CFPAC-1 cell line supplemented 
with 8 μg/ml polybrene (Sigma-Aldrich) and, after 
48h of infection, cells were then selected for stable 
silencing using 2 µg/ml Puromycin (Sigma-Aldrich). For 
quantitative mRNA expression analysis, a polymerase 
chain reaction (PCR) was carried out with total cDNA and 
the SYBR Green PCR Master Mix (LifeTechnologies), 
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with a two-step amplification protocol. mRNA expression 
of target genes was normalized using the mRNA level of 
β-Actin.
Plasmid construction and mutagenesis
The total RNA from CFPAC-1 cell lines was 
extracted using the RNeasy Mini kit (Qiagen, Milan, 
Italy). RNA concentration and purity was determined 
using a NanoDrop instrument (Thermo Scientific by 
VWR, Milan, MI, Italy), and 1µg of the total RNA was 
used as a template for cDNA synthesis using the iScript 
cDNA synthesis kit (BioRad, Segrate, MI, Italy). Using the 
specific primers (Supplementary data TableS2) encoding 
for ENO1, cDNA was amplified by PCR; amplification 
products were analyzed on 1% agarose gels, and isolated 
from gels by using a Gel Extraction Kit (Qiagen), ligated 
with the EGFP retroviral vector Pallino-GFP [46], using 
the XhoI and NotI restriction sites, transformed into 
Top10 competent cells (LifeTechnologies), and sequenced. 
A mutated form of ENO1, bearing mutations in its 
plasminogen binding sites on lysines, 420, 422 and 434 
(substituted by arginines) was obtained by three different 
point mutations using primers containing K420R, K422R 
and K434R substitutions (TableS2) and the QuikChange 
site-directed mutagenesis kit (Stratagene by Eppendorf, 
Milan, Italy); real-time PCR was performed using the 
C 1000 thermal cycler (BioRad). The PCR product was 
subsequently subjected to sequencing.
Establishment of the PDAC cell line CFPAC-1 
expressing ENO1 and the ENO1 mutant variant
The retrovirus was obtained by transfecting the 
Pallino-GFP vector containing the ENO1 gene or the 
ENO1 mutant variant (K420R, K422R and K434R) into 
the GP-293 packaging cells (Clontech) co-transfected with 
the pVSV-G helper vector (Clontech) using the calcium 
phosphate method. Released retroviruses were collected 
at 24h after transfection, and used for transduction of 
the 3’UTR ENO1-silenced CFPAC-1 (shENO1) cell line 
in the presence of 8 μg/ml polybrene (Sigma-Aldrich). 
After 12h of incubation, complete medium was added 
and cells were cultured for a further 2 days. Cells were 
then analyzed for GFP content on a FACS Calibur flow 
cytometer (BD Biosciences). The CELLQuest TM 
software (BD Biosciences) was used for data acquisition 
and analysis of the cells expressing the full-length 
exogenous ENO1 (shENO1+WT), the triple-mutated 
ENO1 (shENO1+TM), as well as cells expressing the 
empty vector (shENO1+Empty) as a control. Expression 
of protein levels was also analyzed by Western blotting.
Enzyme-Linked Immunosorbent Assay (ELISA)
The plasminogen-binding assay was performed with 
a recombinant human ENO1 (rENO1) protein histidine-tag 
(rENO1 WT) or a mutated form (rENO1 TM), produced as 
previously described [10]. Briefly, rENO1 (2.5 µg/mL in 
0.1 M Na2CO3) was coated in 96-plate well and incubated 
over-night at 4°C. After 2 h of blocking with PBS 3% 
bovine serum albumin (BSA) at RT, plasminogen diluted 
in PBS 1% BSA 0.05% Tween was added at different 
doses for 1 h at RT. After incubation with Streptavidin-
HRP (Sigma) and then with tetramethylbenzidine (TMB) 
(Sigma), the plate was read at the spectrophotometer at a 
wavelength of 450nm. 
Anti-ENO1 mAb levels were measured by ELISA, 
by binding to rENO1 (2 µg/mL in 0.1 M Na2CO3). Sera 
collected before the injection of AAVV and 2 and 5 weeks 
after the injection were diluted at 1:100 in DPBS, and 
antibody concentrations were calculated by regression 
analysis using seven 2-fold serial dilutions starting from 
1µg/mL of anti-ENO1 72/1 mAb for creating a standard 
curve [39].
Construction of the recombinant adeno-associated 
viral vector (AAVV) for the expression of complete 
anti-ENO1 72/1 mAb
Total RNA was extracted from hybridoma 72/1 
cells [43] using the RNeasy Mini Kit (Qiagen), and 
VL and VH genes were amplified by RT-PCR with 
primer pairs LB13 (GAYATTGTGATGACYCAGKC) 
/ Cκ2 (TGGATACAGTTGGTGCAGC) and 
VHB (AGGTSMARCTGCAGSAGTCWGG) / 
CHγ (GGCCAGTGGATAGAC), respectively. 
Amplified fragments were sequenced and re-
amplified with primer pairs VL12-BssHII 
(ATAGCGCGCCGTTTCAGCTCCAGCTTGGT) / VL12-
EcoRV (ACTCGGATATCGTGATGACCCAGGCT) 
for VL and VH14-ApaLI 
(TATAGTGCACTCTCAGGCCTATCTGCAGCAGT)/
VH14-Eag/BspE(TAATTCCGGACGGCCGAAGAGAC
AGTGACCAGAGT) for VH, to allow the reconstitution 
of complete functional light- and heavy-chain genes for 
the anti-ENO1 mAb. Re-amplified V genes were inserted 
into a vector derived from pcDNA3 (Life Technologies) 
containing the sequences of the constant regions of the 
mouse κ light chain and γ1 heavy chain arranged in a 
single transcriptional unit, where the light chain and 
heavy chain genes are separated by a sequence encoding 
the autocatalytic peptide 2A from the FMD Virus; the two 
genes contained in this bicistronic mRNA are translated 
into a single polypeptide that spontaneously cleaves into 
two distinct proteins [47]. To remove the residual peptide 
2A, a sequence encoding a furin cleavage site (RSKR) 
was introduced between the light-chain and the peptide 
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2A coding sequences [48]. The VL sequence was inserted 
into BssHII/EcoRV in this bicistronic vector, in order to 
join it to the κ constant region gene, while the VH segment 
was firstly inserted into ApaLI/BspEI in a pUT-SEC vector 
[49], in order to provide it with a sequence encoding a 
secretion signal; the SEC-VH unit was then excised with 
HindIII/EagI, and joined to the mouse γ1 constant region 
gene in the bicistronic vector, downstream of the light 
chain gene and the 2A sequence. The complete anti-
ENO1 mAb transcriptional unit was then transferred to 
HindIII/XbaI in a plasmid vector, under the control of the 
cytomegalovirus immediate early promoter, to yield the 
final vector pAAV-72/1. To confirm that this vector was 
able to direct the production of functional antibodies, 7 
µg of pAAV-72/1 was used to transfect approximately 
3x106 HEK293 cells using the standard calcium phosphate 
method, and supernatants were used to probe cellular 
extracts from PDAC cells by Western blotting. The 
reactivity of the secreted recombinant mAb was compared 
to that of the original 72/1 mAb (Supplementary data 
Fig. S4). The pAAV-72/1 vector was then used for the 
generation of recombinant AAV (serotype9) in the AVU 
(AAV Vector Unit) Core Facility of the ICGEB (Trieste, 
Italy), as described [50].
In vivo experiments
NOD-SCID IL2Rgammanull (NSG) mice (provided 
by the animal facility of the Molecular Biotechnology 
Center, University of Turin, Italy) were injected in 
the tail vein (i.v.) with 1x105 CFPAC-1 shCTRL or 
shENO1+Empty, shENO1+WT, shENO1+TM cells (in 
0.1 ml DPBS) and the mice were euthanized after 28 days.
SCID-beige mice (Charles River, Calco, LC, Italy) 
or NSG mice were injected in the tail vein (i.v.) with 
1x105 CFPAC-1 cells expressing luciferase (in 0.1 ml 
DPBS), followed by biweekly injections of anti-ENO1 
72/1 mAb (500 μg/mouse) or an isotype-matched control 
antibody. NSG mice were pre-treated for 3 days with the 
same antibodies. In a different set of experiments, NSG 
mice were injected 7 days before the i.v. CFPAC-1 cell 
challenge with 1x1011 genocopies of AAVV expressing 
anti-ENO1 72/1 mAb or control AAVV in femoral 
muscles. For detection of in vivo growth of CFPAC-1 
luciferase-transduced tumor cells, mice were anesthetized 
with 2% isofluorane and given i.p. injections of luciferin 
substrate (100 mg/kg) (Caliper Life Sciences by Promega, 
Milan, Italy),10 min prior to imaging using the IVIS 
Spectrum in vivo Imaging System (Xenogen Corp., 
Alameda, CA, USA). Images were taken on day 0, 14 and 
28 after CFPAC-1 injection (SCID-beige mice) and on 
day 0 and 14 (NSG mice). Images were analyzed using 
Living Image software for the IVIS Spectrum (Xenogen 
Corp.). After 28 days, mice were euthanized and checked 
for metastasis by histological analysis.
For orthotopic experiments, NOD-SCID male 
mice (6–8 weeks old) were obtained from the National 
Laboratory Animal Center, Taiwan, and housed under 
specific pathogen-free conditions according to the 
guidelines of the Animal Care Committee at the National 
Health Research Institutes, Taiwan. On Day 0, PANC-1/M 
cells expressing luciferase (1×106/200 ml per mouse) were 
orthotopically injected into the pancreases of the mice. 
The mice were intravenously administered with the anti-
ENO1 E10A mAb (250 μg/mouse) or its isotype control, 
as indicated, at 2 h and 24 h after tumor inoculation. 
Tissue distribution of the cells was monitored using the 
IVIS in vivo imaging system every 2 weeks for a total of 6 
weeks, as described above. Tumor volumes of metastatic 
tumors were measured using the following formula: length 
(mm) × width2 (mm2) × (π/6). All organs from the mice 
treated with the anti-ENO1 E10A or control mAb, as well 
as of age-matched healthy mice were also weighed. In all 
experiments, five mice were used in each group.
Tissue sample and histopathology
Mice were euthanized, necropsied and examined 
for the presence of tumor masses. Tumor masses and 
main organs, including lungs, spleens, and livers were 
fixed in 4% (v/v) neutral-buffered formalin (Sigma-
Aldrich) overnight, transferred to 70% ethanol, followed 
by paraffin-embedding. For histological analysis, 5μm 
formalin-fixed paraffin-embedded tissue sections were cut 
and stained with hematoxylin-eosin. Tumor/normal tissue 
ratios were evaluated with ImageJ software.
Statistical Analysis
The Student’s t test (GraphPad Prism 5 Software, 
San Diego, CA) was used to evaluate the differences in 
the invasion test, and in in vivo experiments. Values were 
expressed as mean ± SEM.
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